Erratum: Parry EM, Alder JK, Qi X, Chen JJ-L, Armanios M. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood. 2011;117(21):5607-5611.

Publikováno v: Blood [Blood] 2016 Apr 07; Vol. 127 (14), pp. 1837.

A real-world comparison of commercial use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.

Autor: Looka A; Dana-Farber Cancer Institute, boston, Massachusetts, United States., Qualls DA; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Matthews D; Dana-Farber Cancer Institute, United States., Redd RA; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Sakellis C; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Duffy C; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Dela Cruz J; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Saucier A; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Armand P; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Crombie JL; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Fisher DC; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Jacobsen ED; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Kim AI; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., LaCasce AS; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Merryman RW; Dana Farber Cancer Institute, Boston, Massachusetts, United States., Parry EM; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Jacobson CA; Dana-Farber Cancer Institute, Boston, Massachusetts, United States.

Publikováno v: Blood advances [Blood Adv] 2024 Nov 15. Date of Electronic Publication: 2024 Nov 15.

The molecular map of CLL and Richter's syndrome.

Autor: Sud A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Department of Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: amit_sud@dfci.harvard.edu., Parry EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA. Electronic address: erinm_parry@dfci.harvard.edu., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Department of Medicine, Brigham and Women's Hospital, Boston, MA.

Publikováno v: Seminars in hematology [Semin Hematol] 2024 Apr; Vol. 61 (2), pp. 73-82. Date of Electronic Publication: 2024 Jan 23.

A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.

Autor: Merryman RW; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA. Reid_merryman@dfci.harvard.edu., Redd RA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Freedman AS; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Ahn IE; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Crombie JL; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Fisher DC; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Jacobsen ED; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Kim AI; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., LaCasce AS; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Ng S; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Odejide OO; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Parry EM; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Isufi I; Hematology, Yale University School of Medicine, New Haven, CT, USA., Kline J; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA., Cohen JB; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA., Mehta-Shah N; Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA., Bartlett NL; Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA., Mei M; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA., Kuntz TM; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Wolff J; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rodig SJ; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Jacobson CA; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA.

Publikováno v: Annals of hematology [Ann Hematol] 2024 Jan; Vol. 103 (1), pp. 185-198. Date of Electronic Publication: 2023 Oct 18.

ZNF683 marks a CD8 ⁺ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome.

Autor: Parry EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Lemvigh CK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Health Technology, Technical University of Denmark, 2800 Kongens Lyngby, Denmark., Deng S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dangle N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ruthen N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Knisbacher BA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Broséus J; Inserm UMRS1256 Nutrition-Génétique et Exposition Aux Risques Environnementaux (N-GERE), Université de Lorraine, 54000 Nancy, France; Université de Lorraine, CHRU-Nancy, Service d'hématologie Biologique, Pôle Laboratoires, 54000 Nancy, France., Hergalant S; Inserm UMRS1256 Nutrition-Génétique et Exposition Aux Risques Environnementaux (N-GERE), Université de Lorraine, 54000 Nancy, France., Guièze R; CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France; EA 7453 (CHELTER), Université Clermont Auvergne, 63001 Clermont-Ferrand, France., Li S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Zhang W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Johnson C; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Long JM; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA; Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA 02115, USA., Yin S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Werner L; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Anandappa A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Purroy N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Gohil S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Oliveira G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA., Bachireddy P; Department of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Shukla SA; Department of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Huang T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Khoury JD; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA., Thakral B; Department of Hematopathology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Dickinson M; Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Tam C; Alfred Health, Melbourne, VIC, Australia; Monash University, Melbourne, VIC, Australia., Livak KJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Getz G; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Neuberg D; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Feugier P; Inserm UMRS1256 Nutrition-Génétique et Exposition Aux Risques Environnementaux (N-GERE), Université de Lorraine, 54000 Nancy, France; Université de Lorraine, CHRU Nancy, service d'hématologie clinique, Nancy, France., Kharchenko P; Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02215, USA., Wierda W; Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Olsen LR; Department of Health Technology, Technical University of Denmark, 2800 Kongens Lyngby, Denmark., Jain N; Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: Catherine_wu@dfci.harvard.edu.

Publikováno v: Cancer cell [Cancer Cell] 2023 Oct 09; Vol. 41 (10), pp. 1803-1816.e8. Date of Electronic Publication: 2023 Sep 21.